Merck Sharp + Dohme Corp.

89bio, Inc.

Cephalon, Inc.

Sunesis Pharmaceuticals, Inc.

Melody McWherter

Craig A Stump

Kathy Schirripa

Harold G Selnick

Robert L Hudkins

Mark E Fraley

Casey Cameron McComas

Ping Liu

Chun Sing Li

Helen J Mitchell

Craig A Zificsak

Andrew John Cooke

Qinghua Mao

Xu-Fang Zhang

Michael R Wood

Allison L Zulli

Harold B Wood

Yi-Heng Chen

David B Whitman

Swati P Mercer

Ian M Bell

Craig Alan Coburn

Melissa S Egbertson

James C Barrow

Jianming Bao

Shaun R Stauffer

Wenjin Yang

Shawn J Stachel

Douglas C Beshore

C Blair Zartman

Dongfang Meng

Kerim Babaoglu

Donnette D Staas

Lou Anne Neilson

Thomas G Steele

Zhi-Qiang Yang

Kenneth E Rittle

Keith P Moore

June J Kim

Zhiqi Qi

Dann Parker

Georgia B McGaughey

Jane Yang Wu

Bruce Fahr

Wanli Lu

Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.

Spiropiperidine derivatives

Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses. 

The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. 

TrKA kinase inhibitors, compositions and methods thereof

The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. 

TRKA kinase inhibitors, compositions and methods thereof

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. 

TrkA kinase inhibitors, compositions and methods thereof

The present invention is directed to compounds of the formula: (wherein variables A, A, A, G, G, G, G, J, E, E, E, R, R, and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Monocyclic CGRP receptor antagonists

Compounds of formula I: (wherein variables A, m, n, J, R, R, R, E, E, E, Rand Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups

The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Growing community of inventors

Boyertown, PA, United States of America

Melody McWherter